Cognition Therapeutics Announces Dosing of First Patient in MAGNIFY Study of Oral CT1812 for Geographic Atrophy Secondary to Dry AMD
11 Julho 2023 - 8:30AM
Cognition Therapeutics, Inc. (NASDAQ: CGTX) announced that it has
dosed the first participant in the Phase 2 MAGNIFY study of CT1812,
an experimental therapy being developed for the treatment of
geographic atrophy (GA) secondary to dry age-related macular
degeneration (dry AMD). The MAGNIFY study (COG2201, NCT05893537) is
a randomized, placebo-controlled trial that is expected to enroll
approximately 246 adults, who have been diagnosed with dry AMD with
measurable GA. In contrast with many development-stage dry AMD
therapies that are administered by intravitreal injection, CT1812
will be given orally, once daily for 24 months to determine if it
can slow disease progression as measured by changes in GA lesion
size.
Dr. David R. P. Almeida, a vitreoretinal surgeon and the
president, CEO and director of clinical research at Erie Retinal
Surgery in Erie, PA enrolled the first participant in MAGNIFY. Dr.
Almeida commented, “Until recently there were no FDA-approved
medications for our patients with dry AMD. Given the complex nature
of dry AMD, even with an approved complement inhibitor, it is
likely that a significant proportion of patients may need and
benefit from a drug that mitigates the disease progression through
a unique mechanism of action. My colleagues and I are excited to be
able to participate in the MAGNIFY study. I am in sincere gratitude
to our patients who support our search for novel therapeutics and
I’m thankful for the dedication and skill I see working with our
Cognition Therapeutics partners to explore the potential of CT1812
in our patients.”
Dry AMD is characterized by a progressive deterioration of the
macula, a region of the retina particularly dense in photoreceptors
that is responsible for central vision. The RPE cells support
photoreceptors by recycling their outer layers, which are shed
daily – a process that is essential for the retina’s
health. CT1812 is a small-molecule, orally delivered, sigma-2
(σ-2) receptor modulator that has been shown to rescue RPE cells in
culture from damaging elements such as pathogenic proteins and
oxidative stress, which disrupt the normal functions of RPE cells
and eventually result in cell death.
Lisa Ricciardi, president and CEO of Cognition, said, “As Dr.
Almeida mentioned, dry AMD is complex with many underlying disease
drivers. Our research suggests that a σ-2 modulator, such as
CT1812, has the potential to protect RPE cells from several of
these key drivers, which may allow patients to retain their visual
acuity for longer. We look forward to working with Dr. Almeida and
our other investigators to explore this possibility in the MAGNIFY
study.”
About CT1812CT1812 is an experimental orally
delivered small molecule sigma-2 (σ-2) receptor modulator designed
to penetrate the blood-retinal barrier and bind selectively and
saturably to the σ-2 receptor complex. The σ-2 receptor complex is
involved in the regulation of key cellular processes such as
membrane trafficking and autophagy that are damaged by toxic
interaction with soluble beta amyloid (Aβ) oligomers, oxidative
stress and other stressors. Cognition’s clinical program will
assess if regulating these processes by modulating the σ-2 receptor
with CT1812 can maintain homeostatic function.
About Geographic Atrophy Secondary to Dry
AMDDry AMD, one of two forms of AMD, is common among
people over 50 and is caused by degeneration and thinning of the
macula, the part of the retina responsible for central vision. The
gradual loss of central vision associated with dry AMD can present
limitations in reading and driving. As the disease progresses in
severity into geographic atrophy, which affects approximately 5
million people worldwide and 1 million in the United States,
degeneration of retinal pigment epithelial (RPE) cells can result
in permanent vision loss.
About Cognition Therapeutics, Inc.Cognition
Therapeutics, Inc. is a clinical-stage biopharmaceutical company
engaged in the discovery and development of innovative, small
molecule therapeutics targeting age-related degenerative disorders
of the central nervous system and retina. We are currently
investigating our lead candidate CT1812 in clinical programs in
Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry
age-related macular degeneration (dry AMD). We believe CT1812 and
our pipeline of σ-2 receptor modulators can regulate pathways that
are impaired in these diseases. We believe that targeting the σ-2
receptor with CT1812 represents a mechanism functionally distinct
from other current approaches in clinical development for the
treatment of degenerative diseases. More about Cognition
Therapeutics and its pipeline can be found at http://cogrx.com.
Forward-Looking StatementsThis press release
contains forward-looking statements within the meaning of The
Private Securities Litigation Reform Act of 1995. All statements
contained in this press release, other than statements of
historical facts or statements that relate to present facts or
current conditions, including, but not limited to, statements
regarding our product candidates, including CT1812, and any
expected or implied benefits or results, our clinical development
plans, including statements regarding our expected timing of the
Phase 2 MAGNIFY trial, are forward-looking statements. These
statements involve known and unknown risks, uncertainties and other
important factors that may cause our actual results, performance,
or achievements to be materially different from any future results,
performance, or achievements expressed or implied by the
forward-looking statements. In some cases, you can identify
forward-looking statements by terms such as “may,” might,” “will,”
“should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,”
“intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “forecast,” “potential” or “continue” or the
negative of these terms or other similar expressions. We have based
these forward-looking statements largely on our current
expectations and projections about future events and financial
trends that we believe may affect our business, financial
condition, and results of operations. These forward-looking
statements speak only as of the date of this press release and are
subject to a number of risks, uncertainties and assumptions, some
of which cannot be predicted or quantified and some of which are
beyond our control. Factors that may cause actual results to differ
materially from current expectations include, but are not limited
to: competition; our ability to secure new (and retain existing)
grant funding; our ability to grow and manage growth, maintain
relationships with suppliers and retain our management and key
employees; our ability to successfully advance our current and
future product candidates through development activities,
preclinical studies and clinical trials and costs related thereto;
uncertainties inherent in the results of preliminary data and
pre-clinical studies being predictive of the results of clinical
trials; the timing, scope and likelihood of regulatory filings and
approvals, including regulatory approval of our product candidates;
changes in applicable laws or regulations; the possibility that the
we may be adversely affected by other economic, business or
competitive factors, including ongoing economic uncertainty; our
estimates of expenses and profitability; the evolution of the
markets in which we compete; our ability to implement our strategic
initiatives and continue to innovate our existing products; our
ability to defend our intellectual property and the risks and
uncertainties described in the “Risk Factors” section of our annual
and quarterly reports filed with the Securities & Exchange
Commission. These risks are not exhaustive and we face both known
and unknown risks. You should not rely on these forward-looking
statements as predictions of future events. The events and
circumstances reflected in our forward-looking statements may not
be achieved or occur, and actual results could differ materially
from those projected in the forward-looking statements. Moreover,
we operate in a dynamic industry and economy. New risk factors and
uncertainties may emerge from time to time, and it is not possible
for management to predict all risk factors and uncertainties that
we may face. Except as required by applicable law, we do not plan
to publicly update or revise any forward-looking statements
contained herein, whether as a result of any new information,
future events, changed circumstances or otherwise.
Contact Information:Cognition Therapeutics,
Inc.info@cogrx.com
Aline Sherwood (media)Scienta
Communicationsasherwood@scientapr.com
Daniel Kontoh-Boateng (investors)Tiberend Strategic Advisors,
Inc.dboateng@tiberend.com
Cognition Therapeutics (NASDAQ:CGTX)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Cognition Therapeutics (NASDAQ:CGTX)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024